Table 1 Social, demographic and clinical data of SLE patients in control and therapy groups
Patients (n = 80) | Control (n = 43) | Therapy (n = 37) | P value |
|---|---|---|---|
Age mean (SD)* | 42.7 (11.3) | 42.0 (12.3) | 0.798 |
Disease duration mean (SD)** | 11.6 (8.2) | 12.4 (7.8) | 0.511 |
Educationa n (%)*** | 0.625 | ||
≤ 3 years | 05 (11.6) | 03 (8.1) | |
4–8 years | 16 (37.2) | 10 (27.0) | |
9–11 years | 05 (11.6) | 08 (21.6) | |
12–15 years | 16 (37.2) | 14 (37.8) | |
≥ 16 years | 01 (2.3) | 02 (5.4) | |
Socioeconomic classa n (%)*** | 0.846 | ||
A/B | 00 (.0) | 00 (.0) | |
C | 26 (60.5) | 20 (54.1) | |
D | 12 (27.9) | 12 (32.4) | |
E | 05 (11.6) | 05 (13.5) | |
Race n (%)*** | 0.642 | ||
White | 22 (54.2) | 17 (45.9) | |
Afro descendants | 21 (45.8) | 20 (54.1) | |
Religion n (%)*** | 0.121 | ||
Catholic | 17 (39.5) | 22 (59.5) | |
Evangelic | 13 (30.2) | 13 (35.1) | |
Spiritualist | 05 (11.6) | 01 (2.7) | |
Jehovah witness | 04 (9.3) | 01 (2.7) | |
Buddhist | 01 (2.3) | 00 (.0) | |
No religion | 03 (7.0) | 00 (.0) | |
Lupus medications n (%)*** | |||
Azathioprine | 11 (25.6) | 09 (24.3) | 0.897 |
Hydroxychloroquine | 25 (58.1) | 19 (51.4) | 0.542 |
Prednisone | 24 (55.8) | 21 (56.8) | 0.932 |
Neuropsychiatric medications n (%)*** | |||
Amitriptyline | 07 (16.3) | 06 (16.2) | 0.994 |
Cyclobenzaprine | 03 (7.0) | 02 (5.4) | 0.770 |
Fluoxetine | 09 (20.9) | 07 (18.9) | 0.882 |
SLICC/ACR-DI b n (%)*** | 0.055 | ||
Zero | 22 (51.2) | 11 (29.7) | |
1.00 | 12 (27.9) | 17 (45.9) | |
2.00 | 06 (14.0) | 02 (5.4) | |
3.00 | 03 (7.0) | 04 (10.8) | |
4.00 | 00 (.0) | 03 (8.1) | |